The strong EPS beat and increased revenue, combined with positive pipeline catalysts (WVE-007 Phase 2a initiation, WVE-006 data in May), support a bullish near-term outlook. Watch for the May 18 investor webcast for RestorAATion-2 data and Phase 2a enrollment start for INLIGHT.
WVE drugs
WVE drug pipeline →Price Chart
Executive Summary
Wave Life Sciences reported Q1 2026 EPS of -$0.13, beating consensus estimates of -$0.34 by 61.8%, and revenue of $38.2M (up 316% YoY from $9.2M). The beat was driven by higher milestone revenue from the GSK collaboration, while pipeline progress for obesity candidate WVE-007 (FDA-accepted Phase 2a) and RNA editing program WVE-006 (upcoming data) reinforced the bullish thesis.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $38.2M vs $9.2M YoY, up 316%
- Net loss per share -$0.13 vs -$0.29 YoY; beat consensus -$0.34 by 61.8%
- Cash and cash equivalents $544.6M, runway into 3Q 2028
- FDA accepted Phase 2a multidose portion of INLIGHT trial for WVE-007 (obesity); initiation on track for 2Q 2026
- RestorAATion-2 data for WVE-006 (AATD) to be presented in May 2026, with regulatory feedback on accelerated approval expected mid-2026
- GSK collaboration milestone payments contributed to revenue growth
Financial Impact
EPS beat of $0.21 vs consensus, revenue surge of $29M YoY
Risk Factors
- Clinical trial failures or delays for WVE-007 or WVE-006
- Regulatory setbacks on accelerated approval pathway for WVE-006
- Cash burn rate may accelerate with Phase 2a expansion
- Competition from GLP-1 drugs in obesity market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-183563 |
| Document: d135689dex992.htm | 0001193125-26-183563 |
| Document: d135689d8k.htm | 0001193125-26-183563 |
| Document: 0001193125-26-183563-index-headers.html | 0001193125-26-183563 |
| Document: 0001193125-26-183563-index.html | 0001193125-26-183563 |
| Document: 0001193125-26-183563.txt | 0001193125-26-183563 |
| 8-K Data (Synthetic) | 0001193125-26-183563 |
Track record
16 reports on WVE
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.42% at T+5 after the Mar 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.13 to $2.87 Now $2.87 −8.31% ▼ −8.31% −6.40% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $3.64 to $3.63 Now $2.87 −21.15% ▼ −0.27% +0.11% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Neutral 5/10 Entry $3.45 to $3.64 Now $2.87 −16.81% ▲ +5.51% +5.16% vs SPY
- Oct 14, 20264w ago DEF 14A Neutral 4/10 Entry $3.19 to $3.13 Now $2.87 −10.03% ▼ −1.88% −0.77% vs SPY
- Sep 30, 20266w ago Press Release Bullish 5/10 Entry $3.70 to $3.88 Now $2.87 −22.43% ▲ +4.86% +4.69% vs SPY
- Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $5.41 to $5.09 Now $2.87 −46.95% ▼ −5.92% −5.44% vs SPY
- May 18, 202626w ago Press Release Bullish 7/10 Entry $6.14 to $6.19 Now $2.87 −53.26% ▲ +0.81% −0.23% vs SPY
- Apr 28, 202628w ago 8-K Bullish 7/10 Viewing No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers